Lingzhi

Other Names

Agarico-igniarium trullaAgaricus lignosusBoletus castaneusBoletus crustatusBoletus flabelliformisBoletus laccatusBoletus lucidusBoletus ramulosum var. flabelliformisBoletus rugosusBoletus supinusBoletus supinus var. castaneusBoletus verniceuschizhiFomes lucidusGanoderma laccatumGanoderma lingzhiGanoderma lucidumGanoderma nitensGanoderma sichuanenseglossy ganodermaGrifola lucidaherb of spiritual potencyhijiridakekadodetakelacquered bracketling chiling chihling zhilingzhicaolinh chimannentakemulingzhimushroom of immortalitynấm linh chiPolyporus laccatusPolyporus lucidusreishireishi mushroomruicaoruizhishenzhishiny polyporusvarnished conkvarnished shelfxiancaoyeong jiyeongjiyeongjibeoseotyung geezizhi万年茸仙草木靈芝灵芝瑞芝瑞草神芝紫芝赤芝霊芝靈芝靈芝草영지

Synopsis

Lingzhi (Ganoderma lucidum complex): A Comprehensive Reference

1. Identity, Nomenclature, and Taxonomy

Names and Synonyms

Lingzhi is a mushroom used in both medicine and food, with a long history in China, Japan, Korea, and other Asian countries. It carries common names in different languages: Lingzhi in China, Reishi in Japan, Youngzhi in Korea, and Linh chi in Vietnam. In Chinese, the name lingzhi represents a combination of spiritual potency and essence of immortality, and is regarded as the "herb of spiritual potency," symbolizing success, well-being, divine power, and longevity. The generic epithet Ganoderma derives from the Greek ganos ("brightness; sheen") and derma ("skin"), while the specific epithet lucidum is Latin for "shining."

Taxonomic Position and Species Complexity

Ganoderma lucidum is a highly regarded medicinal fungus belonging to the Basidiomycota class, Polyporaceae family, and Ganoderma genus. Currently, there are approximately 120 recognized species of the Ganoderma genus worldwide.

The taxonomy of the fungus commercially sold as lingzhi is considerably more complex than the single-species label implies. The taxonomy of Ganoderma species remains controversial, since they were initially classified on the basis of their morphological characteristics. Recently, it was proposed that G. lucidum from China be renamed as G. sichuanense or G. lingzhi. Three-gene combined analyses (ITS+IGS+rpb2) indicated that the Chinese "G. lucidum" shared almost identical sequences with G. sichuanense. Based on both morphological and molecular data, the identity of the Chinese "G. lucidum" (Ling-zhi) is considered conspecific with G. sichuanense. Strains from Europe and North America, which were regarded as true G. lucidum, were positioned in a clearly different group.

An ethanol extract of ground basidiocarps from G. lucidum (European strain) contains much less triterpenic acids than found in the extract of G. lingzhi (East Asian strain). The high amount of triterpenic acids accounts for the bitter taste of the basidiocarps of G. lingzhi and of its ethanol extract. This has direct relevance for commercial products, as the two species differ chemically and cannot be used interchangeably.

The genus Ganoderma is comprised of more than 200 species; however, only G. lucidum (W. Curtis Fr.) P. Karst and G. sinense Zhao, Xu et Zhang are recognized in the Chinese Pharmacopoeia as "Ling-zhi" having similar pharmacological effects.

Morphology

Ganoderma lucidum is a large, dark mushroom with a glossy exterior and a woody texture. The Latin word lucidus means "shiny" or "brilliant" and refers to the varnished appearance of the surface of the mushroom. Among cultivated mushrooms, G. lucidum is unique in that its pharmaceutical rather than nutritional value is paramount.

2. Traditional and Historical Use

Earliest Records

Ling-zhi is a famous fungus for its medicinal values, well documented in the Chinese literature which can be dated back nearly two thousand years to the Shen Nong Materia Medica (102–200 AD). The first book wholly devoted to the description of herbs and their medicinal value was Shen Nong Ben Cao Jing, written in the Eastern Han dynasty of China (25–220 AD). This book is also known as the "Classic of the Materia Medica" or "Shen-nong's Herbal Classics." This book divided medicines into three classes — upper, middle, and lower — according to their efficacy and toxicity. The upper grades are all effective and non-toxic, and G. lucidum is listed as the upper grade.

As recorded in the Shen Nong Ben Cao Jing, Ganoderma had the efficacy of improving immunity, soothing the nerves, helping sleep, protecting the liver, detoxification, anti-aging and prolonging life expectancy.

Cultural Significance

Lingzhi symbolizes happiness, good fortune, good health, and even immortality in Chinese traditional culture. The proliferation of G. lucidum images in art began in 1400 AD, and they are associated with Taoism. However, G. lucidum images extended beyond religion and appeared in paintings, carvings, furniture, and even women's accessories. Due to its rarity in nature, for many years Reishi was reserved exclusively for emperors and important officials. This polypore was traditionally used by Taoist monks to improve meditative practices and attain a long and healthy life.

Traditional Chinese Medicine (TCM) Applications

In TCM, Ling-zhi is used for nourishing and tonifying Qi of Zang organs, as well as nourishing Qi and blood. The Chinese Pharmacopoeia recorded that it has the effects of invigorating Qi and tranquilizing spirit, relieving cough and asthma, and can be used for restlessness, insomnia, palpitations, lung deficiency, cough and asthma, consumption and shortness of breath, and loss of appetite.

Traditional preparations from Reishi were used to enhance stamina, immunity, and to treat inflammatory diseases such as arthritis, asthma, bronchitis, hepatitis, and nephritis, and were also used for the treatment of various cancers. The tranquilizing effect of G. lucidum was recorded in "Shennong's herbal classic" as early as the first century BC and is currently listed in the Chinese Pharmacopoeia.

Preparations in Traditional Use

Reishi mushrooms are unusual as they are primarily used as a medicinal agent rather than a food, and are available as crude drug, powders, dietary supplements, and teas. The pharmaceutical and traditional medicine products are prepared from the mycelia, spores, and fruiting bodies.

Spread Beyond China

Ganoderma lucidum belongs to basidiomycetes, with a woody texture, widely distributed in tropical and temperate regions in Europe, North America, and Asia. It is a kind of mushroom used for both medicine and food, with a long history in China, Japan, Korea, and other Asian countries. Successful cultivation was first achieved in China in 1969, and the mushroom has since been commercially cultivated on a large scale globally.

3. Key Constituents and Active Compounds

Overview of Phytochemistry

Research has established that G. lucidum possesses important bioactive compounds including polysaccharides, triterpenoids, sterols, proteins, nucleotides, fatty acids, vitamins, and minerals, which have been demonstrated to exhibit multiple biological effects. Phytochemicals identified in Ganoderma lingzhi include triterpenes, polysaccharides, coumarin, mannitol, alkaloids, ganoderol, ganoderenic acid, ganoderiol, ganodermanontriol, lucidadiol, and ganodermadiol.

Polysaccharides and Beta-Glucans

Ganoderma lucidum polysaccharide (GLP) is one of the main bioactive substances in G. lucidum, with anti-tumor, anti-oxidation, anti-cancer, and other biological activities. GLP is closely related to human health. High-molecular-weight β-glucans activate macrophage surface receptors through triple-helix conformations, whereas sulfation enhances electrostatic interactions with immune cells. Mechanistically, polysaccharides regulate macrophage polarization, dendritic cell maturation, and T/B cell activation, engaging core signaling pathways such as TLR4/MyD88/NF-κB, NLRP3 inflammasome, and MAPK.

Polysaccharides enhance immune function by activating macrophages, natural killer cells, and T cells, thereby promoting phagocytosis and cytokine production. Recent research further demonstrates that polysaccharides can reshape the gut microbiota–immune metabolic axis by promoting the production of short-chain fatty acids (SCFAs) and activating receptors such as GPR43, indirectly modulating systemic immune responses.

Triterpenoids (Ganoderic Acids)

Triterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum. G. lucidum is the only known source of a particular group of triterpenes, also known as ganoderic acids, which have been found to have direct cancer cell cytotoxicity on a wide variety of cancer cell lines.

Triterpenoids contribute through anti-inflammatory and antioxidant activities, inhibiting inflammatory mediators and protecting tissues from damage. Ganoderma lucidum also influences immune regulation via key signaling pathways, including NF-κB and MAPK, and supports immune tolerance, potentially reducing the risk of autoimmune diseases.

There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, macrophage-like differentiation, activation of the MAP-K pathway, an IL-3-dependent cytotoxic action, the induction of cytoprotective autophagy, and induction of apoptosis. This compound has been tested in twenty-six different human cancer cell types and has shown anti-proliferative activity, especially in leukemia, lymphoma, and myeloma lines.

Sterols, Proteins, and Other Constituents

The primary bioactive components of G. lucidum include polysaccharides, triterpenoids, peptides/proteins, and sterols, each contributing to multifaceted health benefits. G. lucidum spore oil (GLSO) is a lipid component extracted from broken-walled Ganoderma spores using supercritical CO₂ extraction technology. GLSO contains fatty acids, Ganoderma triterpenes, sterols, and other bioactive compounds.

The polysaccharides, triterpenoids, proteins, and phenolic compounds in Ganoderma exhibit antimicrobial effects by targeting bacterial cell walls, disrupting membrane integrity, and inhibiting key microbial enzymes. These compounds are effective against a wide range of bacteria, including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and various fungi.

Anti-Inflammatory Mechanisms

Ganoderma lucidum triterpenes are bioactive compounds with recognized anti-inflammatory, antitumor, and immunomodulatory properties. A systematic review synthesized evidence regarding the anti-inflammatory activity of these triterpenes based on studies from the last two decades. Across diverse experimental models, these compounds consistently demonstrated the ability to modulate inflammatory responses, irrespective of whether they were administered as isolated molecules or as components of crude extracts.

4. Scientific Evidence by Area of Use

4.1 Immunomodulation

Ganoderma lucidum (Lingzhi) is renowned for its immunomodulatory, anti-inflammatory, and antioxidant properties, primarily attributed to its bioactive components such as polysaccharides and triterpenoids. Research focuses on the mechanisms by which Ganoderma lucidum modulates immune responses. Additionally, it modulates gut microbiota, which further impacts systemic immunity.

Clinical/Human Evidence: Clinical studies have demonstrated that G. lucidum polysaccharides enhance host immune functions, including enhanced natural killer (NK) cell activity, in patients with advanced solid tumors, although an objective tumor response was not observed. One open-label study enrolled thirty-six patients treated with 5.4 g/day Ganopoly for 12 weeks. In a non-randomized open clinical trial, 74 advanced colorectal cancer patients were administered GLP at a dose of 5.4 g/day for 12 weeks, and treatment increased the mitogenic reactivity to PHA, counts of CD3, CD4, CD8, and CD56 lymphocytes, and plasma concentrations of IL-2, IL-6, and IFN-γ.

Polysaccharides and triterpenoids demonstrate promising clinical application prospects in metabolic diseases, inflammatory conditions, neurodegenerative disorders, and cancer immunotherapy. Despite these promising applications, further research is needed to fully elucidate the molecular mechanisms and potential of Ganoderma lucidum in precision medicine.

Evidence strength: Immunomodulatory effects on immune-cell populations are among the best-documented effects in human subjects, but most trials are small, non-randomized, or lack placebo control; overall evidence is preliminary.

4.2 Oncology (Adjuvant Use in Cancer)

Ganoderma lucidum is a natural medicine widely used and recommended by Asian physicians and naturopaths for its supporting effects on the immune system. Laboratory research and a handful of preclinical trials have suggested that G. lucidum carries promising anticancer and immunomodulatory properties.

Cochrane Systematic Review: Five RCTs met the inclusion criteria and were included in a Cochrane review. Two independent review authors assessed the methodological quality of individual trials. The meta-analysis results showed that patients who had been given G. lucidum alongside chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone (RR 1.50; 95% CI 0.90 to 2.51, P = 0.02). The results showed that chemotherapy/radiotherapy combined with G. lucidum enhanced tumor response by 1.27-fold. G. lucidum increased host immune functions, especially the percentage of CD3, CD4, and CD8 lymphocytes. It was concluded that G. lucidum may improve long-term survival in patients with advanced cancer. It should not be used as first-line therapy, but because of the general stimulatory effect on the host immune system and enhancement in tumor response, it can be used as an adjuvant therapy.

Cancer-Related Fatigue: In a pilot RCT, 48 breast cancer patients with cancer-related fatigue undergoing endocrine therapy were randomized into experimental or control groups. FACT-F, HADS, and EORTC QLQ-C30 questionnaires were administered at baseline and 4 weeks after treatment. The experimental group showed statistically significant improvements in physical well-being and fatigue subscale, reported less anxiety and depression and better quality of life. Immune markers of cancer-related fatigue were significantly lower, and no serious adverse effects occurred during the study.

Future studies should emphasize the improvement in methodological quality, and further clinical research on the effect of G. lucidum on cancer long-term survival is needed.

Evidence strength: Some positive signals from RCTs in the adjuvant oncology setting, but trial quality is variable, sample sizes are small, and the Cochrane review's confidence intervals are wide. Evidence is insufficient to establish G. lucidum as a standalone cancer treatment.

4.3 Cardiovascular Risk Factors (Glucose, Lipids, Blood Pressure)

Some human studies with intervention lengths of 4–12 weeks in patients with type 2 diabetes mellitus or hypertension have reported improvements in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose, insulin, and C-peptide, total cholesterol, LDL cholesterol, and blood pressure, whilst other studies have reported no changes in glucose parameters, and unchanged LDL cholesterol. However, for all these clinical trials reporting positive results, the reporting of methods was poor and unclear, with a high potential for bias.

Key Rigorous RCT: Eighty-four participants with type 2 diabetes mellitus and metabolic syndrome were randomised to one of three intervention groups: Ganoderma lucidum, Ganoderma lucidum with Cordyceps sinensis, or placebo. The dosage was 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks. The primary outcome measure was blood glucose (glycosylated haemoglobin and fasting plasma glucose). The combined intervention had no effect on any of the primary outcomes (HbA1c = 0.13%, 95% CI [−0.35, 0.60], p = 0.60; FPG = 0.03 mmol/L, 95% CI [−0.90, 0.96], p = 0.95) or secondary outcome measures over the course of the 16-week trial, and there was no overall increased risk of adverse events with either active treatment.

Cochrane Systematic Review (Cardiovascular): Three studies from which data were used for statistical analyses compared G. lucidum (1.4 g to 3 g per day) to placebo over 12 to 16 weeks. No improvement was found for fasting plasma glucose (WMD 0.30 mmol/L; 95% CI −0.95 mmol/L to 1.55 mmol/L). There were no statistically significant differences between groups for blood pressure or triglycerides. Evidence from a small number of randomised controlled trials does not support the use of G. lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus.

In a clinical trial involving 45 STEMI and non-STEMI patients, polysaccharides of G. lucidum (750 mg/day in 3 divided doses for 90 days) decreased the levels of IL-1 and TNF-α, as well as MDA levels. In vitro and diabetic rodent studies suggest that Ganoderma lucidum can improve blood glucose and serum insulin levels, whilst protecting pancreatic islets from free radical damage.

Evidence strength: The most rigorous RCTs and the Cochrane review do not support beneficial effects on blood glucose or lipids at the doses studied. Earlier positive findings come from poorly controlled trials. Evidence remains insufficient.

4.4 Hepatoprotection

G. lucidum exhibits a broad range of hepatoprotective impacts in various liver disorders, such as hepatic cancer, nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease, hepatitis B, hepatic fibrosis, and liver injury induced by carbon tetrachloride (CCl₄) and α-amanitin. G. lucidum protects the liver through a broad range of mechanisms that include the modulation of liver Phase I and II enzymes, the suppression of β-glucuronidase, antifibrotic and antiviral actions, the regulation of the production of nitric oxide (NO), the maintenance of hepatocellular calcium homeostasis, immunomodulatory activity, and scavenging free radicals.

Evidence strength: Hepatoprotective mechanisms are largely documented in preclinical (in vitro and animal) studies. Robust human clinical trials specifically targeting liver outcomes are limited.

4.5 Sleep and Neurological Effects

It was reported that G. lucidum improved the sleep of patients with insomnia or other mental disorders. Furthermore, G. lucidum promoted sleep in pentobarbital-treated mice and rats. The acidic part of the alcohol extract of G. lucidum mycelia (GLAA) was studied in mice. Administration of 25, 50, and 100 mg/kg GLAA for 28 days promoted sleep by shortening sleep latency and prolonging sleeping time. GLAA administration increased the levels of the sleep-promoting neurotransmitter 5-hydroxytryptamine and relevant transcripts in the serotonergic synapse pathway in the hypothalamus.

In 2018, a clinical study reported that weekly seizure frequency was reduced in patients with epilepsy after administering G. lucidum spore powder. In recent years, more and more literature has reported the pharmacological effects of Ganoderma on neuroprotection. Numerous research works on the neuroprotective effects of Ganoderma have been documented, including modulation of neurogenesis, amelioration of Alzheimer's disease, therapeutic effect on epilepsy, and the protective effect on neural cells in stroke injury.

Evidence strength: Sleep promotion is documented in preclinical models with a plausible serotonin-mediated mechanism; limited clinical data exist. Neuroprotective effects are largely experimental.

4.6 Antimicrobial Effects

Ganoderma has garnered attention for its broad therapeutic properties, particularly its potent antimicrobial activities. Research focuses on the mechanisms of action and bioactive compounds responsible for the ability of Ganoderma to inhibit various pathogenic microorganisms. This body of evidence remains largely preclinical (in vitro), and no clinical trials in humans have established G. lucidum as an antimicrobial therapeutic agent.

5. Body Systems and Health Areas Associated with Lingzhi

Immune system: Polysaccharides enhance immune function by activating macrophages, natural killer cells, and T cells, thereby promoting phagocytosis and cytokine production.
Liver/hepatic system: Traditionally used to prevent and treat liver disorders.
Cardiovascular system: Research has shown activities against cardiovascular disease, including effects on lipids, blood pressure, obesity, diabetes, and antioxidant and radical scavenging properties.
Central nervous system: Across Chinese dynasties, Ganoderma was attributed efficacy in improving immunity, soothing the nerves, helping sleep, protecting the liver, detoxification, anti-aging, and prolonging life expectancy.
Respiratory system: TCM recorded it for relieving cough and asthma, and for use in cases of lung deficiency.
Gut microbiota: Additionally, it modulates gut microbiota, which further impacts systemic immunity.

6. Dosage Forms and Dosages Reported in Studies

Commercial Forms

A variety of commercial G. lucidum products are available in various forms, such as powders, dietary supplements, and tea. These are produced from different parts of the mushroom, including mycelia, spores, and fruiting body. Other products are prepared with materials (e.g., polysaccharides, triterpenes) extracted, usually with hot water or ethanol, from fruiting bodies or mycelia harvested from submerged liquid cultures, then evaporated to dryness and tabletted/encapsulated either separately or in designated proportions.

Although spore preparations have been researched and promoted vigorously in recent years, any added medicinal effects attributable to the removal or breakage of spore walls, which represents an additional and often costly step in the production process, are still controversial. The adoption of supercritical fluid CO₂ extraction technologies has enlarged the spectrum of extracted substances due to the low temperature required during processing.

Dosages Used in Clinical Studies

In an open-label study of immune function in patients with advanced lung cancer: 5.4 g/day of water-soluble G. lucidum polysaccharides (Ganopoly) for 12 weeks in 36 patients.
In a non-randomized trial of 74 advanced colorectal cancer patients: GLP at a dose of 5.4 g/day for 12 weeks.
In a double-blind RCT of metabolic syndrome: 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks.
In a randomised, double-blind, cross-over cardiovascular study: 1.44 g Lingzhi daily or matching placebo for 12 weeks in 26 patients.
In a clinical trial of 45 STEMI/non-STEMI patients: 750 mg/day of G. lucidum polysaccharides in 3 divided doses for 90 days.
In a small trial of 16 healthy volunteers: 4000 mg daily of a Ganoderma supplement (containing 1.89% terpenoids and 15.8% polysaccharides) for 10 days, with no adverse effects reported.

There are no scientific data on a safe and effective dosage of Ganoderma lucidum. Dosages vary substantially across studies, and preparations differ in their content of active compounds, making direct comparisons difficult.

7. Safety Considerations and Interactions

General Tolerability

β-Glucan derived from G. lucidum has been designated as "generally recognized as safe" (GRAS) by the U.S. Food and Drug Administration (FDA). Systematic review of Ganoderma spore powder has indicated no serious adverse effects and no abnormalities in hepatic or renal function; gastrointestinal concerns are among the more commonly reported side effects with Ganoderma supplementation. G. lucidum was generally well tolerated by most participants, with only a scattered number of minor adverse events. No major toxicity was observed across the studies.

Acute, subchronic, and genetic toxicity studies have shown no toxicity or adverse effects, insignificant side effects, or low toxicity at extremely high experimental doses, with an LD₅₀ of 38.3 g/kg by intragastric administration reported.

Participants who took G. lucidum for four months were 1.67 times (RR 1.67, 95% CI 0.86 to 3.24) more likely to experience an adverse event than those who took placebo, but these were not serious side effects.

Hepatotoxicity

Hepatotoxicity from Ganoderma lucidum has appeared in only two case reports as of the time of that publication. The advertised reputation of Lingzhi consumption, including its hepatoprotective properties, is far more prevalent than published adverse events. A common problem is the dichotomy between preferring anecdotal proof over scientific evidence, as complementary and alternative medicines are often more attractive due to their presumed "non-toxic natural" origins.

Anticoagulant and Antiplatelet Interactions

Several studies have demonstrated that Ganoderma lucidum can compromise hemostasis because of its antithrombotic and anticoagulant activity. A case was reported of a patient on hemodialysis on ongoing anticoagulant therapy with warfarin. Two consecutive elevated INR values of 6.92 and 8.22 were recorded. Anamnesis revealed a recent ingestion of two 500 mg tablets of Ganoderma lucidum extracts just before each occasion.

A systematic review in the British Journal of Clinical Pharmacology identified and reported on the potential risk of interaction between warfarin and Ganoderma lucidum. Therefore, G. lucidum broken spore supplements should be avoided in patients with unstable liver function or any patients using antiplatelets or anticoagulants.

Cytochrome P450 Interactions

The dichloromethane extract of G. lucidum displayed broad inhibitory effects on CYPs, with triterpenoids as the main bioactive constituents, which may induce potential drug–drug interactions. This information should be helpful for the rational use of G. lucidum in promoting human health. The CYP inhibitory potential means that G. lucidum could theoretically alter the metabolism of drugs that are substrates of these enzymes, though the clinical significance of this requires further investigation.

Compositional Variability and Standardization

The structure and composition of G. lucidum compounds and products vary according to the geographical origin of the strain, cultivation methods, the stage of development (basidiocarp, spores, mycelium), extraction procedures, standardization techniques, product development, and commercial batch. The great wealth of chemical data and anecdotal evidence on the effects of G. lucidum needs to be complemented by reliable experimental and clinical data from well-designed human trials. Many challenges are encountered due to a range of factors from dosage to production quality. Strategies for enhancing quality control procedures to define and standardize G. lucidum preparations are needed to determine mechanisms of action and to help characterize the active component(s).

Overall Evidence Assessment and Research Gaps

Despite its established status as a functional food and potential therapeutic agent, G. lucidum remains an underexplored resource in modern nutraceutical and pharmaceutical research. Notably, few bioactive compounds derived from this mushroom have been clinically validated as superior to existing therapies for disease treatment. Polysaccharides and triterpenoids demonstrate promising clinical application prospects in metabolic diseases, inflammatory conditions, neurodegenerative disorders, and cancer immunotherapy. Despite these promising applications, further research is needed to fully elucidate the molecular mechanisms and potential of Ganoderma lucidum in precision medicine.

References

Health Conditions

Health conditions that Lingzhi may help support.

No conditions available.

Body Systems

Body systems that Lingzhi may help support.

No body systems available.